Navigation Links
De nouvelles directives recommandent la fidaxomicine pour tous les patients pouvant suivre un traitement antibiotique par voie orale pour une infection à Clostridium difficile
Date:10/29/2013

est une étape importante pour la réduction de la morbidité et de la mortalité associée à l'ICD », déclare le professeur Oliver Cornely de l'hôpital universitaire de Cologne en Allemagne. « J'approuve ces directives et je pense que l'application de ces recommandations améliorera le traitement de l'ICD et réduira le fardeau à la fois pour les patients et les systèmes de santé. »

Deux importantes études cliniques de phase III comparant l'efficacité et l'innocuité de 400 mg par jour fidaxomicine par voie orale à 500 mg par jour de vancomycine ont permis de montrer les avantages potentiels de la fidaxomicine par rapport à la vancomycine qui est le traitement habituel.[9],[11] Les patients participant à ces essais présentaient un diagnostic confirmé d'ICD et incluaient des patients classés comme souffrant d'une ICD grave ainsi que des patients pour lesquels l'ICD constituait un risque particulièrement important comme les personnes âgées[11] ou avec des pathologies concomitantes.[12],[13],[14] La fidaxomincine a permis de réduire considérablement le taux de récurrence de l'ICD comparé à la vancomycine et les patients traités avec la fidaxomicine étaient plus susceptibles de ne plus souffrir de diarrhées sans récurrence 30 jours après la fin du traitement, que les patients traités avec de la vancomycine.[9],[11] La fidaxomicine a également atteint son critère d'évaluation principal de taux de guérison clinique qui était équivalent à celui de la vancomycine.[9],[11]

Certaines populations courent un risque plus élevé d'ICD et sont particulièrement vulnérables. L'ICD peut être as
'/>"/>

SOURCE Astellas Pharma Europe Ltd
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Medicare Procurement Program Creates Extreme Hardships For North Carolina Patients, Says AAHomecare
2. Strong Efficacy Data Prompt Charleston Laboratories to Halt Phase 3 Study of CL-108 in Patients with Moderate to Severe Acute Pain
3. Lumena Pharmaceuticals Initiates the CLARITY Phase II Study of LUM001 in Patients with Primary Biliary Cirrhosis
4. 3SBio to Develop DJ5 for Progressive Renal Failure in ADPKD Patients
5. Juventas Therapeutics completes enrollment of Phase II STOP-HF study of JVS-100 in patients with symptomatic heart failure
6. Medicare Procurement Program Creates Extreme Hardships for Patients without Options, Says AAHomecare
7. Media Sourcerys Secure Mobile Workflow App Deployed by CCS Medical to Expedite Product Delivery to Patients
8. Lamotrigine is One of the Most Commonly Prescribed Drugs Among Newly Diagnosed Bipolar Disorder Patients in the United States
9. Among Newly Diagnosed Type 2 Diabetes Patients, DPP-IV Inhibitors are the Leading Oral Therapies After Standard Metformin and Sulfonylurea
10. Should Mircera Reach the U.S. Market, Surveyed Nephrologists State that at Least 40 Percent of CKD-ND and Dialysis Patients are Likely Candidates
11. Ampio Pharmaceuticals subsidiary Luoxis Diagnostics announces positive summary data from study of traumatic brain injury patients and issuance of companys third US patent for its oxidation-reduction potential diagnostic platform
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... SINGAPORE , March 2, 2015 Mount ... center in Singapore to treat ... radiosurgery from Varian Medical Systems (NYSE: VAR ... introduced the new system, which enables advanced forms of ... shaped high-energy radiation beams to attack a tumor from ...
(Date:3/2/2015)... 2015 Valencia Technologies Corporation (" Valencia ... its radically small device for the treatment of high ... this randomized, double-blinded, controlled trial are compelling and provide ... it will succeed in a large U.S. trial for ... Valencia has successfully raised more ...
(Date:3/2/2015)... , March 2, 2015  CytomX, a ... of cancer, today announced the creation of scientific ... and clinicians in the fields of cancer immunotherapy ... new advisory boards will provide guidance to CytomX ... of precision immunotherapies and Probody drug conjugates. The ...
Breaking Medicine Technology:Mount Elizabeth Novena Hospital to Deliver First TrueBeam STx Radiosurgery Treatments in Singapore 2Mount Elizabeth Novena Hospital to Deliver First TrueBeam STx Radiosurgery Treatments in Singapore 3Valencia Technologies Implants its 48th Patient, Continues Equity Crowdfunding 2CytomX Expands Scientific and Clinical Advisory Boards with Leading Experts in Cancer Immunotherapy and Antibody Drug Conjugates 2CytomX Expands Scientific and Clinical Advisory Boards with Leading Experts in Cancer Immunotherapy and Antibody Drug Conjugates 3
... Following recent FDA approvals for prostate cancer treatment ... that the lives of men with advanced prostate cancer ... medication from Johnson & Johnson. The drug, which could reach ... news with the potential to change clinical practice by ...
... SPRING, Md., Oct. 13 The Food and Drug Administration ... a rare type of thigh bone fracture in people ... (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ) (Logo: ... warning because the rare type of fracture has been ...
Cached Medicine Technology:Robotic Prostatectomy Expert Dr. David Samadi, MD Discusses Prostate Cancer Treatment Drug Abiraterone 2
(Date:3/2/2015)... March 02, 2015 Robins & Morton ... conjunction with Women in Construction Week (March 1-7, sponsored ... NAWIC) and National Women’s History Month, Robins & Morton ... affect the company and the construction industry as a ... to the dozens of roles in between, each woman ...
(Date:3/2/2015)... The Workgroup for Electronic Data Interchange (WEDI), ... health IT to create efficiencies in healthcare information exchange, ... Providers.” The white paper by WEDI’s ICD-10 Testing Subworkgroup ... testing by focusing on primary considerations and steps for ... October 1, 2015 implementation date. Download the white ...
(Date:3/2/2015)... This year, the National Multiple Sclerosis Society’s annual ... for people across the country to unite, raise awareness, ... live their best lives. MS Awareness Week is a special ... join the Society’s vision of a world free of MS. ... of the central nervous system, interrupts the flow of information ...
(Date:3/2/2015)... March 02, 2015 Four Seasons Resort Maui ... its 25th anniversary this year, having officially opened its doors ... luxury resort is honoring over 70 employees who started on ... from amongst the approximately 400 original employees. The celebration ... Oceanfront Lawn. , This Four Seasons flagship resort, ...
(Date:3/2/2015)... March 02, 2015 What are the ... physicians request references? When are interviews scheduled, how can ... opportunities?, Both training and practicing physicians who are looking ... questions and more at the PracticeLink Physician Career Advancement ... drop-in Job Fair is from 5:30 to 8:30 p.m. ...
Breaking Medicine News(10 mins):Health News:Robins & Morton Recognizes Women In Construction 2Health News:WEDI Releases New White Paper on ICD-10 Testing for Small Providers 2Health News:Every Connection Counts During MS Awareness Week 2Health News:Every Connection Counts During MS Awareness Week 3Health News:Every Connection Counts During MS Awareness Week 4Health News:Celebrating Four Seasons Resort Maui’s 25th Anniversary 2Health News:PracticeLink to Host a Career Advancement Workshop and Job Fair in Houston 2
... , , Hospitals, ... , PRINCETON, N.J., Aug. 18 Twelve New ... federal government to test an innovative new incentive method that aims ... , The three-year trial program could serve as a ...
... KONG, Aug. 18 IBM (NYSE: IB M ... Life Insurance Company Limited (NYSE: CI ), has implemented ... continuity in the event of disasters or other incidents that could ... (Logo: http://www.newscom.com/cgi-bin/prnh/20090416/ I BMLOGO ) ...
... 18 EwingCole, a nationally recognized architectural, engineering, interior ... today announced that it will combine its practice with ... with a robust portfolio of healthcare projects. The ... September 1, 2009, will create the Delaware Valley,s largest ...
... , , ... systems for targeted, less-invasive medical treatments, today announced that Massachusetts ... iCT, making it second in the nation and third in ... successfully integrate intra-operative imaging -- from high-field MRI to multi-slice ...
... , ARLINGTON, Va., Aug. 18 "Proposed ... add billions of dollars of un-reimbursed cost to the Medicare ... K.C. McAlpin, executive director of ProEnglish, a national organization that ... the United States. , , The ...
... ELM GROVE, Wis., Aug. 18 Long wait times can ... safety . Many hospitals constantly struggle with moving patients in need of critical ... bed. Compirion Healthcare Soluti o ns is ... Improving Patient Flow - ED to Inpatient , free of charge ...
Cached Medicine News:Health News:Medicare Picks N.J. to Test Innovative Incentive System 2Health News:Medicare Picks N.J. to Test Innovative Incentive System 3Health News:Medicare Picks N.J. to Test Innovative Incentive System 4Health News:CIGNA Provides Peace-of-mind for APAC Customers by Ensuring Business Continuity and Resilience with IBM 2Health News:CIGNA Provides Peace-of-mind for APAC Customers by Ensuring Business Continuity and Resilience with IBM 3Health News:CIGNA Provides Peace-of-mind for APAC Customers by Ensuring Business Continuity and Resilience with IBM 4Health News:EwingCole, RDLA Join Together, Creating Architecture/Engineering Firm With Largest Healthcare Focus in the Delaware Valley 2Health News:EwingCole, RDLA Join Together, Creating Architecture/Engineering Firm With Largest Healthcare Focus in the Delaware Valley 3Health News:Massachusetts General Hospital is Second in Nation to Acquire Both BrainSUITE(R) iMRI and iCT 2Health News:Free Compirion Bed Flow Webinar Helps Improve Patient Flow From ED to Inpatient Units 2Health News:Free Compirion Bed Flow Webinar Helps Improve Patient Flow From ED to Inpatient Units 3
For the quantitative determination of Creatine Kinase in serum....
For the quantitative determination of creatine kinase in serum. Kinetic Reaction measured at 340 nm. Linearity: 1500 IU/L at 37C....
For the quantitative determination of total glucose in serum....
Intended for the quantitative determination of glucose in serum. Reaction: endpoint. Wavelength: 500 nm. Linearity: 500 mg/dL (27.8 mmol/L)....
Medicine Products: